Sunshine Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
SBFM$2.75+1.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Defined Terms
Unless the context requires otherwise, references to “Sunshine,” “the Company,” “we,” “us” or “our” in this Form 10-K refer to Sunshine Biopharma, Inc. and its subsidiaries. The following are definitions for terms or abbreviations used in this Form 10-K:
| Adva-27a | The laboratory designation of the Company’s chemotherapy small molecule under development |
|---|---|
| ASC | Accounting Standards Codification |
| ASU | Accounting Standards Update issued by FASB |
| CAD | Canadian Dollar |
| COSO | Committee of Sponsoring Organizations of the Treadway Commission |
| COVID-19 | Novel coronavirus disease of 2019 |
| DIN | Drug Identification Number, an eight-digit number issued by Health Canada authorizing the sale of a drug in Canada |
| EPS | Earnings per share |
| EUA | Emergency Use Authorization |
| FASB | Financial Accounting Standards Board |
| FDA | U.S. Food and Drug Administration |
| FDIC | Federal Deposit Insurance Corporation |
| FTC | Federal Trade Commission |
| G&A | General and administrative |
| GAAP | Generally Accepted Accounting Principles |
| GMP | Good Manufacturing Practice |
| GST | Goods and Services Tax (Canada) |
| Health Canada | The Canadian drug regulatory body |
| IND | Investigational New Drug |
| IT | Information Technology |
| LNP | Lipid Nano Particle |
| K1.1 mRNA | The laboratory designation of the Company’s mRNA based anticancer therapy under development |
| MD&A | Management’s Discussion and Analysis of Financial Condition and Results of Operations |
| MERS-CoV | Middle East Respiratory Syndrome Coronavirus |
| Mpro | Coronavirus main protease |
| mRNA | Messenger ribonucleic acid |
| NDA | New Drug Application |
| NOC | A Notice of Compliance issued by Health Canada to a drug manufacturing facility |
| Nora Pharma | Nora Pharma Inc., a wholly-owned subsidiary of the Company acquired on October 20, 2022 |
| NPN | Natural Product Number, an eight-digit number issued by Health Canada authorizing the sale of a natural product or a supplement in Canada |
| OTC | Over-The-Counter |
| pCPA | pan-Canadian Pharmaceutical Alliance, an alliance of the provincial, territorial and federal governments that determines generic drugs pricing based on a percentage of the brand-name reference products |
| PCT | Patent Cooperation Treaty |
| PLpro | Coronavirus papain-like protease |
| QST | Quebec Sales Tax (Canada) |
| R&D | Research and Development |
| ROU | Right of Use |
| SARS Coronavirus | Severe Acute Respiratory Syndrome Coronavirus, the group of coronaviruses that includes SARS-CoV-2, MERS-CoV, and SARS-CoV |
| SARS-CoV | Severe Acute Respiratory Syndrome Coronavirus that first appeared in 2003 |
| SARS-CoV-2 | Severe Acute Respiratory Syndrome Coronavirus 2, the virus that causes COVID-19 |
| SBFM-PL4 | Laboratory designation of the Company’s COVID-19 treatment under development |
| SEC | U.S. Securities and Exchange Commission |
| SOC | Security Operations Center |
| street name | Securities held in the name of a brokerage firm on behalf of a client |
| Sunshine Canada | Sunshine Biopharma Canada Inc., a wholly owned subsidiary of the Company |
| U.S. | United States of America |
| USD | U.S. Dollars. All applicable references in this report refer to US Dollars and not Canadian Dollars (CAD) unless otherwise specifically stated. |
i
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.